Johnson & Johnson is pushing a combination therapy for inflammatory bowel disease into pivotal testing despite the treatment's failure in two mid-stage trials. The company confirmed it will advance JNJ-4804, which combines the blockbuster drug Tremfya with another experimental agent, into Phase 3 studies.
The decision underscores the high stakes in the competitive IBD market, where J&J already markets Tremfya for psoriasis and psoriatic arthritis. By moving forward despite disappointing data, the firm signals confidence in the drug's long-term potential or a strategy to salvage significant development investments.
Specific efficacy data from the Phase 2 trials were not disclosed, though the company acknowledged the therapy did not meet its primary endpoints. J&J did not provide details on how it plans to adjust dosing, patient selection, or trial design for the next phase of development.
If successful, JNJ-4804 could strengthen J&J's gastroenterology portfolio and challenge established rivals like AbbVie's Skyrizi. However, the path to approval remains uncertain, and the mid-stage failures raise questions about the mechanism's validity and the company's risk tolerance.
Some analysts caution that advancing a failed therapy without clear mid-stage improvements could backfire, potentially eroding investor confidence if Phase 3 results also disappoint. The company has not released full trial data for independent review.